Scandion Oncology A/S (SCOL) - Net Assets
Based on the latest financial reports, Scandion Oncology A/S (SCOL) has net assets worth Skr8.27 Million SEK (≈ $889.77K USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr18.28 Million ≈ $1.97 Million USD) and total liabilities (Skr10.01 Million ≈ $1.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read SCOL total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr8.27 Million |
| % of Total Assets | 45.23% |
| Annual Growth Rate | 28.2% |
| 5-Year Change | -94.7% |
| 10-Year Change | N/A |
| Growth Volatility | 357.4 |
Scandion Oncology A/S - Net Assets Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's net assets have evolved over time, based on quarterly financial data. Also explore SCOL total asset value for the complete picture of this company's asset base.
Annual Net Assets for Scandion Oncology A/S (2017–2024)
The table below shows the annual net assets of Scandion Oncology A/S from 2017 to 2024. For live valuation and market cap data, see SCOL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr8.27 Million ≈ $889.77K |
-73.43% |
| 2023-12-31 | Skr31.12 Million ≈ $3.35 Million |
-55.75% |
| 2022-12-31 | Skr70.33 Million ≈ $7.57 Million |
-32.73% |
| 2021-12-31 | Skr104.54 Million ≈ $11.25 Million |
-32.93% |
| 2020-12-31 | Skr155.87 Million ≈ $16.77 Million |
+749.94% |
| 2019-12-31 | Skr18.34 Million ≈ $1.97 Million |
+45.89% |
| 2018-12-31 | Skr12.57 Million ≈ $1.35 Million |
+765.25% |
| 2017-12-31 | Skr1.45 Million ≈ $156.34K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Scandion Oncology A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24052316400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr17.25 Million | 208.70% |
| Other Components | Skr232.55 Million | 2812.64% |
| Total Equity | Skr8.27 Million | 100.00% |
Scandion Oncology A/S Competitors by Market Cap
The table below lists competitors of Scandion Oncology A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rockfire Resources plc
LSE:ROCK
|
$103.69K |
|
Pennant International Group plc
LSE:PEN
|
$104.15K |
|
Taptica International Ltd
LSE:TAP
|
$104.19K |
|
Stora Enso Oyj ser. R
ST:STE-R
|
$104.45K |
|
Tower Resources plc
LSE:TRP
|
$103.37K |
|
Conroy Gold & Natural Resources Plc
LSE:CGNR
|
$102.99K |
|
Titon Holdings Plc
LSE:TON
|
$102.65K |
|
Gresham House Renewable Energy VCT 1 plc
LSE:GV1O
|
$102.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandion Oncology A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,122,000 to 8,268,000, a change of -22,854,000 (-73.4%).
- Net loss of 36,658,000 reduced equity.
- New share issuances of 20,206,000 increased equity.
- Other factors decreased equity by 6,402,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-36.66 Million | -443.37% |
| Share Issuances | Skr20.21 Million | +244.39% |
| Other Changes | Skr-6.40 Million | -77.43% |
| Total Change | Skr- | -73.43% |
Book Value vs Market Value Analysis
This analysis compares Scandion Oncology A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr0.20 | Skr0.00 | x |
| 2018-12-31 | Skr1.23 | Skr0.00 | x |
| 2019-12-31 | Skr1.22 | Skr0.00 | x |
| 2020-12-31 | Skr4.82 | Skr0.00 | x |
| 2021-12-31 | Skr3.11 | Skr0.00 | x |
| 2022-12-31 | Skr1.64 | Skr0.00 | x |
| 2023-12-31 | Skr0.76 | Skr0.00 | x |
| 2024-12-31 | Skr0.04 | Skr0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandion Oncology A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -443.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.21x
- Recent ROE (-443.37%) is below the historical average (-121.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -104.58% | 0.00% | 0.00x | 1.35x | Skr-1.66 Million |
| 2018 | -65.10% | 0.00% | 0.00x | 1.08x | Skr-9.44 Million |
| 2019 | -66.44% | -5930.37% | 0.01x | 1.09x | Skr-14.02 Million |
| 2020 | -10.44% | 0.00% | 0.00x | 1.20x | Skr-31.86 Million |
| 2021 | -49.46% | 0.00% | 0.00x | 1.11x | Skr-62.16 Million |
| 2022 | -109.06% | 0.00% | 0.00x | 1.27x | Skr-83.73 Million |
| 2023 | -125.97% | 0.00% | 0.00x | 1.11x | Skr-42.32 Million |
| 2024 | -443.37% | 0.00% | 0.00x | 2.21x | Skr-37.48 Million |
Industry Comparison
This section compares Scandion Oncology A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandion Oncology A/S (SCOL) | Skr8.27 Million | -104.58% | 1.21x | $103.58K |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more